207 related articles for article (PubMed ID: 37852570)
21. Mast cells as target in cancer therapy.
Groot Kormelink T; Abudukelimu A; Redegeld FA
Curr Pharm Des; 2009; 15(16):1868-78. PubMed ID: 19519429
[TBL] [Abstract][Full Text] [Related]
22. Controversial role of mast cells in skin cancers.
Varricchi G; Galdiero MR; Marone G; Granata F; Borriello F; Marone G
Exp Dermatol; 2017 Jan; 26(1):11-17. PubMed ID: 27305467
[TBL] [Abstract][Full Text] [Related]
23. IL33 and Mast Cells-The Key Regulators of Immune Responses in Gastrointestinal Cancers?
Eissmann MF; Buchert M; Ernst M
Front Immunol; 2020; 11():1389. PubMed ID: 32719677
[TBL] [Abstract][Full Text] [Related]
24. Stromal infiltrating mast cells identify immunoevasive subtype high-grade serous ovarian cancer with poor prognosis and inferior immunotherapeutic response.
Cao K; Zhang G; Zhang X; Yang M; Wang Y; He M; Lu J; Liu H
Oncoimmunology; 2021; 10(1):1969075. PubMed ID: 34527431
[TBL] [Abstract][Full Text] [Related]
25. Taking a Full Snapshot of Cancer Biology: Deciphering the Tumor Microenvironment for Effective Cancer Therapy in the Oncology Clinic.
Dzobo K
OMICS; 2020 Apr; 24(4):175-179. PubMed ID: 32176591
[TBL] [Abstract][Full Text] [Related]
26. The critical role of mast cell-derived hypoxia-inducible factor-1α in regulating mast cell function.
Liang X; Yin G; Ma Y; Xu K; Liu J; Li J
J Pharm Pharmacol; 2016 Nov; 68(11):1409-1416. PubMed ID: 27671226
[TBL] [Abstract][Full Text] [Related]
27. Mast Cell-Tumor Interactions: Molecular Mechanisms of Recruitment, Intratumoral Communication and Potential Therapeutic Targets for Tumor Growth.
Segura-Villalobos D; Ramírez-Moreno IG; Martínez-Aguilar M; Ibarra-Sánchez A; Muñoz-Bello JO; Anaya-Rubio I; Padilla A; Macías-Silva M; Lizano M; González-Espinosa C
Cells; 2022 Jan; 11(3):. PubMed ID: 35159157
[TBL] [Abstract][Full Text] [Related]
28. Mast cell marker gene signature: prognosis and immunotherapy response prediction in lung adenocarcinoma through integrated scRNA-seq and bulk RNA-seq.
Zhang P; Liu J; Pei S; Wu D; Xie J; Liu J; Li J
Front Immunol; 2023; 14():1189520. PubMed ID: 37256127
[TBL] [Abstract][Full Text] [Related]
29. Mast cells in tumor growth: angiogenesis, tissue remodelling and immune-modulation.
Maltby S; Khazaie K; McNagny KM
Biochim Biophys Acta; 2009 Aug; 1796(1):19-26. PubMed ID: 19233249
[TBL] [Abstract][Full Text] [Related]
30. Histamine in cancer immunology and immunotherapy. Current status and new perspectives.
Sarasola MP; Táquez Delgado MA; Nicoud MB; Medina VA
Pharmacol Res Perspect; 2021 Oct; 9(5):e00778. PubMed ID: 34609067
[TBL] [Abstract][Full Text] [Related]
31. Extracellular Vesicles as Emerging Players in Intercellular Communication: Relevance in Mast Cell-Mediated Pathophysiology.
Shefler I; Salamon P; Mekori YA
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502083
[TBL] [Abstract][Full Text] [Related]
32. Disruption of Cell-Cell Communication in Anaplastic Thyroid Cancer as an Immunotherapeutic Opportunity.
Chakraborty S; Carnazza M; Jarboe T; DeSouza N; Li XM; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():33-66. PubMed ID: 34888843
[TBL] [Abstract][Full Text] [Related]
33. Immune Regulatory Processes of the Tumor Microenvironment under Malignant Conditions.
Pansy K; Uhl B; Krstic J; Szmyra M; Fechter K; Santiso A; Thüminger L; Greinix H; Kargl J; Prochazka K; Feichtinger J; Deutsch AJ
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948104
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-17-positive mast cells influence outcomes from BCG for patients with CIS: Data from a comprehensive characterisation of the immune microenvironment of urothelial bladder cancer.
Dowell AC; Cobby E; Wen K; Devall AJ; During V; Anderson J; James ND; Cheng KK; Zeegers MP; Bryan RT; Taylor GS
PLoS One; 2017; 12(9):e0184841. PubMed ID: 28931051
[TBL] [Abstract][Full Text] [Related]
35. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.
Mao X; Xu J; Wang W; Liang C; Hua J; Liu J; Zhang B; Meng Q; Yu X; Shi S
Mol Cancer; 2021 Oct; 20(1):131. PubMed ID: 34635121
[TBL] [Abstract][Full Text] [Related]
36. Exosomes Function in Tumor Immune Microenvironment.
Huang Y; Liu K; Li Q; Yao Y; Wang Y
Adv Exp Med Biol; 2018; 1056():109-122. PubMed ID: 29754177
[TBL] [Abstract][Full Text] [Related]
37. Engineering Nanoparticles for Targeted Remodeling of the Tumor Microenvironment to Improve Cancer Immunotherapy.
Gao S; Yang D; Fang Y; Lin X; Jin X; Wang Q; Wang X; Ke L; Shi K
Theranostics; 2019; 9(1):126-151. PubMed ID: 30662558
[TBL] [Abstract][Full Text] [Related]
38. Inflammatory Components of the Thyroid Cancer Microenvironment: An Avenue for Identification of Novel Biomarkers.
Jarboe T; Tuli NY; Chakraborty S; Maniyar RR; DeSouza N; Xiu-Min Li ; Moscatello A; Geliebter J; Tiwari RK
Adv Exp Med Biol; 2021; 1350():1-31. PubMed ID: 34888842
[TBL] [Abstract][Full Text] [Related]
39. mTOR-Mediated Regulation of Immune Responses in Cancer and Tumor Microenvironment.
Mafi S; Mansoori B; Taeb S; Sadeghi H; Abbasi R; Cho WC; Rostamzadeh D
Front Immunol; 2021; 12():774103. PubMed ID: 35250965
[TBL] [Abstract][Full Text] [Related]
40. Immune cell - produced ROS and their impact on tumor growth and metastasis.
Kennel KB; Greten FR
Redox Biol; 2021 Jun; 42():101891. PubMed ID: 33583736
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
